|
 |
|
Volume 1, Number 3, Supplement 1 (September/October 2003) | ||||
| ASCO 2003: Selected Abstracts on Hematopoietic Growth Factors Lee S. Schwartzberg, MD, FACP Guest Editor |
||||
Introduction |
||||
3 |
ASCO 2003: Selected Abstracts on Hematopoietic Growth Factors The West Clinic, Memphis, TN
|
|||
Anemia |
||||
6 |
Every-2-Week Darbepoetin Alfa Improves Fatigue and Energy Rating Scores in Cancer Patients Undergoing Chemotherapy M. D. Anderson Cancer Center, Houston, TX; Watson Clinic, LLP, Lakeland, FL; Hematology and Oncology Specialists, New Orleans, LA; Associates in Oncology and Hematology, Chattanooga, TN; Harbor View Cancer Center, Baltimore, MD; Rush Cancer Institute, Chicago, IL; and Amgen Inc, Thousand Oaks, CA
| |||
8 |
Darbepoetin Alfa Administered Every Two Weeks (Q2W) Reduces Chemotherapy-Induced Anemia (CIA) to the Same Extent as Recombinant Human Erythropoietin (rHuEPO) but With Less-Frequent Dosing Center for Oncology Research & Treatment, Dallas, TX; Highlands Oncology Group, Springdale, AR; Pacific Cancer Medical Center, Anaheim, CA; Nazha Cancer Center, Northfield, NJ; Pacific Shores Medical Group, Long Beach, CA; Kentucky Cancer Clinic, Hazard, KY; Northeast Arkansas Clinic, Jonesboro, AR; and Amgen Inc, Thousand Oaks, CA
| |||
10 |
Darbepoetin Alfa Every 2 Weeks to Treat Chemotherapy-Induced Anemia: Experience in a Randomized, Open-Label Study Wilshire Oncology Medical Group, Pomona, CA; Hematology Oncology Consultants, Columbus, OH; Hutchinson Clinic, P.A., Hutchinson, KS; Franklin Square Hospital Center, Baltimore, MD; Gainesville Hematology Oncology Associates, Gainesville, FL; Lawrence & Memorial Hospital, New London, CT; and Amgen Inc, Thousand Oaks, CA
| |||
12 |
Epoetin Alfa 40,000 U Once Weekly Maintains Hemoglobin in Advanced Non–Small-Cell Lung Cancer Patients Receiving First-Line Chemotherapy Anemia Prevention in NSCLC Study Group; Duke University Medical Center, Durham, NC; University of Alabama, Birmingham, AL; University of Missouri, Columbia, MO; University of Pittsburgh Cancer Institute, Pittsburgh, PA; and Ortho Biotech Products, L.P., Bridgewater, NJ
| |||
14 |
Drug Use Evaluation of Darbepoetin Alfa in Anemic Patients Undergoing Chemotherapy Supports a Fixed Dose of 200 µg Given Every 2 Weeks (Q2W) US Oncology, Southwest Regional Cancer Center, Houston, TX; Amgen Inc, Thousand Oaks, CA; and Cancer Centers of the Carolinas, Greenville, SC
| |||
16 |
Epoetin Alfa 60,000 U Once Weekly Followed by 120,000 U Every Three Weeks Maintains Hemoglobin Levels in Anemic Cancer Patients Receiving Chemotherapy: Final Report Tennessee Oncology, Nashville, TN, and Ortho Biotech Products, L.P., Bridgewater, NJ
| |||
18 |
Front-Loaded Darbepoetin Alfa With Q3W Maintenance Administered as a Fixed or Weight-Based Dose in Anemic Cancer Patients Results in Similar Efficacy Profiles The Darbepoetin Alfa 20010102 Study Group; St. Elizabeth’s Medical Center, Boston, MA; Arena Oncology Associates, Great Neck, NY; Rhinelander Regional Medical Center, Rhinelander, WI; Amgen Inc, Thousand Oaks, CA; and The West Clinic, Memphis, TN
| |||
20 |
Optimizing Management of Chemotherapy-Induced Anemia: A Combined Analysis of Data Using a Darbepoetin Alfa Front-Loading/Maintenance Approach The West Clinic, Memphis, TN; St. Elizabeth’s Medical Center, Boston, MA; Amgen Inc, Thousand Oaks, CA; and UCLA School of Medicine, Los Angeles, CA
| |||
22 |
Early and Sustained Improvement in Health-Related Quality of Life (HRQOL) Was Observed With Front-Loaded Darbepoetin Alfa Compared to Conventional Therapy The 20000174 & 980290 Study Groups; UCLA School of Medicine, Los Angeles, CA; Pacific Shores Medical Group, Long Beach, CA; and Amgen Inc, Thousand Oaks, CA
| |||
24 |
Once-Weekly Epoetin Alfa Maintains Hemoglobin, Improves Quality of Life, and Reduces Transfusion in Breast Cancer Patients Receiving Chemotherapy Canadian Eprex Study Group; Durham Regional Cancer Centre, Oshawa, ON, Canada, and Hotel-Dieu de Levis and Hotel-Dieu de Quebec, Levis, QC, Canada
| |||
26 |
Prediction of Hemoglobin Non-Response in Studies of Darbepoetin Alfa Compared With Epoetin Alfa to Treat Chemotherapy-Induced Anemia University of Liege, Liege, Belgium; UCLA School of Medicine, Los Angeles, CA; Joan Karnell Cancer Center, University of Pennsylvania, Philadelphia, PA; and Amgen Inc, Thousand Oaks, CA
| |||
28 |
The Burden of Weekly Epoetin Alfa Injections to Patients and Their Caregivers Dartmouth-Hitchcock Medical Center, Lebanon, NH; Pacific Shores Medical Group, Long Beach, CA; MEDTAP International, Bethesda, MD; Amgen Inc, Thousand Oaks, CA; and South Carolina Oncology Associates, Columbia, SC
| |||
30 |
Assessment of Symptom Burden Using the M. D. Anderson Symptom Inventory (MDASI) in Subjects With Nonmyeloid Malignancies Receiving Multicycle Chemotherapy and Darbepoetin Alfa Every Two Weeks (Q2W) The SURPASS Study Group; Mt Sinai School of Medicine, New York, NY; M.D. Anderson Cancer Center, Houston, TX; Mayo Clinic, Jacksonville, FL; and Amgen Inc, Thousand Oaks, CA
| |||
32 |
Fatigue and Plasma Cytokines in a Randomized Double-Blind Placebo-Controlled Trial of Epoetin Alfa in Patients Undergoing Combined Modality Therapy for Unresectable Non–Small-Cell Lung Cancer (NSCLC) Dartmouth Hitchcock Medical Center, Lebanon, NH
| |||
34 |
Clinical Predictors of Severe Fatigue in Cancer Center’s Emergency Center (EC) The University of Texas M. D. Anderson Cancer Center, Houston, TX
| |||
Neutropenia |
||||
36 |
Most Patients Treated With Adjuvant Chemotherapy for Breast Cancer Receive Substantially Reduced Dose Intensity The ANC Study Group; University of Rochester, Rochester, NY; Duke University, Durham, NC; and University of Washington, Seattle, WA
| |||
38 |
Time to First Neutropenia Hospitalization During Chemotherapy for Non-Hodgkin’s Lymphoma: An Iowa SEER-Medicare Study The University of Iowa College of Public Health, Iowa City, IA; The University of Iowa College of Pharmacy, Iowa City, IA; The University of Iowa Roy J. and Lucille A. Carver College of Medicine, Iowa City, IA; and Amgen, Thousand Oaks, CA
| |||
40 |
Filgrastim Experience in Diverse Nonmyeloid Malignancies: A Prospective Study in Community Oncology Practice Heywood Hospital, Gardner, MA; Missouri Baptist Cancer Center, St. Louis, MO; Brookshire Medical, Downey, CA; Amgen Inc, Thousand Oaks, CA; and Birmingham Hematology/Oncology, Birmingham, AL
| |||
42 |
Minimal Doses and Delayed Timing of Filgrastim (F) May Impact Patient Outcomes as Compared to Pegfilgrastim (PegF) The West Clinic, Memphis, TN
| |||
44 |
Effects of G-CSF Schedule on Leukocyte Recovery and Infection Rate in the CHOP-14 Regimen for Elderly Patients With Aggressive Lymphoma IMISE, Leipzig, Germany, and Universitätskliniken des Saarlandes, Homburg, Germany
| |||
46 |
Patients with Grades III (G3) and IV (G4) Chemotherapy-Induced Neutropenia (CIN) Have Greater Physical and Psychological Symptom Burden The West Clinic, Memphis, TN, and the University of Memphis, Memphis, TN
| |||
48 |
Pilot Adjuvant Study: 12 Weeks of Dose-Dense Doxorubicin (A) With Scheduled G-CSF (G) Support Followed by 4 Cycles of Docetaxel (TXT) Seattle Cancer Care Alliance/University of Washington, Seattle, WA
| |||
50 |
Concomitant Pegfilgrastim (PF) With Weekly Chemotherapy Cancer Center of Boston, Boston, MA
| |||
52 |
A Single Pegfilgrastim (PF) Dose per Cycle Maintains Neutrophil Counts After Docetaxel (Doc) and Gemcitabine (Gem) Chemotherapy for Advanced Non–Small-Cell Lung Cancer (NSCLC) The West Clinic, Memphis, TN
| |||
54 |
Dose-Dense Carboplatin/Vinorelbine With Pegfilgrastim Support for the Treatment of Thoracic Malignancies Duke University Medical Center, Durham, NC`
| |||
56 |
Are Hematopoietic Growth Factors Necessary to Allow the Safe Delivery of Chemotherapy at Efficacious Doses for Early Breast Cancer? Toronto Sunnybrook Regional Cancer Centre, Toronto, ON, Canada
| |||
58 |
Sequential IL-3 and GM-CSF Therapy in Bone Marrow Failure With Long-Term Follow-Up of Responses Departments of Bioimmunotherapy and BMT, M. D. Anderson Cancer Center, Houston, TX
| |||
60 |
Indirect and Direct Costs Associated With a Febrile Neutropenic Event LifeMetrix Information Services, McLean, VA, and Northwestern University, Chicago, IL
| |||
62 |
Drug Reimbursement Needs to Include All Costs Beyond Drug Acquisition, Including Human Resource Utilization Supportive Oncology Services, Monroe, CT, and The West Clinic, Memphis, TN
| |||
Supported by an unrestricted educational grant from Amgen Inc. |
||||
© 2003 by BioLink Communictions, Inc. All rights reserved. No part of this publication may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopy, recording, or any information storage and retrieval system, without permission in writing from the publisher. |
||||
23 kb